“To date, no company has been able to successfully target this well-known cancer pathway with sufficient precision … iOnctura has achieved a new level of precision and could be the first company to develop a clinically meaningful medicine targeting this pathway,” said Bulthuis, who is also a board member at iOnctura.
iOnctura’s drug pipeline includes roginolisib, which is being developed to treat uveal melanoma, a rare eye cancer. The company claims that early trials have successfully treated more than 45 patients.
The market for uveal melanoma treatment is rapidly growing and is expected to be worth $9.56 billion by 2032. iOnctura plans to test the drug’s effectiveness in other cancers, such as lung cancer.
iOnctura Raises €80M For Cancer Drug Work : Expansion of Drug Development
The company will also use part of the funds to develop cambritaxestat, aimed at treating soft tissue tumors. The U.S. Food and Drug Administration has granted cambritaxestat orphan drug designation for potential treatment of pancreatic cancer.
